ABSTRAT
Hypertensive disorders of pregnancy, including gestational hypertension, preeclampsia, and eclampsia, are leading contributors to maternal morbidity and mortality in the US and are associated with adverse neonatal outcomes, including low birth weight, fetal growth restriction, and stillbirth.1 Prenatal cannabis use, identified by self-report or urine toxicology, is rising and occurred in 9.0% of [BLINDED] pregnancies in 2022.2 Our prior work found associations with gestational hypertension and preeclampsia in pregnancies from 2011–2019; however, mode was not systematically collected before 2020.3 Administration modes differ in THC delivery and pharmacokinetics.4 Mode-specific evidence can guide patient-centered counseling and help clinicians identify potentially higher-risk patterns of use. We examined associations between specific modes of prenatal cannabis use and hypertensive disorders of pregnancy.